Method of treating hepatic fibrosis

Details Method of treating hepatic fibrosis Method of treating hepatic fibrosis

2006-06-13

2006-06-13

Henley, III, Raymond J. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07060709

ABSTRACT:
This invention provides the use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the treatment or inhibition of hepatic fibrosis and hepatic cirrhosis.

REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3993749 (1976-11-01), Sehgal et al.
patent: 4401653 (1983-08-01), Eng
patent: 4885171 (1989-12-01), Surendra et al.
patent: 5078999 (1992-01-01), Warner et al.
patent: 5080899 (1992-01-01), Sturm et al.
patent: 5100899 (1992-03-01), Calne
patent: 5206018 (1993-04-01), Sehgal et al.
patent: 5286730 (1994-02-01), Caufield et al.
patent: 5286731 (1994-02-01), Caufield et al.
patent: 5288711 (1994-02-01), Mitchell et al.
patent: 5321009 (1994-06-01), Baeder et al.
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5387589 (1995-02-01), Kulkarni
patent: 5496832 (1996-03-01), Armstrong
patent: 5516781 (1996-05-01), Morris et al.
patent: 5561138 (1996-10-01), Armstrong
patent: 5665772 (1997-09-01), Cottens et al.
patent: 6277983 (2001-08-01), Shaw et al.
patent: 6670355 (2003-12-01), Azrolan et al.
patent: 2002/0061903 (2002-05-01), Zhu
patent: 2002/0061904 (2002-05-01), Zhu et al.
patent: 2004/0077677 (2004-04-01), Ashraf et al.
patent: 0525960 (1996-03-01), None
patent: WO 01/97809 (2001-12-01), None
patent: WO 03/077915 (2003-09-01), None
STN Registry File, RN:162635-04-3 Rapamycin, 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate], entered STN on May 3, 1995.
National Library of Medicine—Medical Subject Headings, 2006 MeSH, Supplementary Concept Data, for Substance “CCI 779”.
Staruch et al, FK506 and Rapamycin Inhibit Murine T Cell Activation Through Different Mechanisms, The FASEB Journal, vol. 3, No. 3 3411, (1989).
Sehgal et al, Rapamycin (AY-22, 989), A New Antifungal Antibiotic, II. Fermentation, Isolation and Characterization, The Journal of Antibiotics, vol. XXVIII No. 10, pp. 727-732 (Oct. 1975).
Vezina et al, Rapamycin (AY-22,989), A New Antifungal Antibiotic I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle, The Journal of Antibiotics, vol. XXVIII No. 10, pp. 721-726 (Oct. 1975).
Baker et al, Rapamycin (AY-22,989), A New Antifungal Antibiotic, III. In Vitro and In Vivo Evaluation, The Journal of Antibiotics, vol. XXXI, No. 6, pp. 539-545, (Jun. 1978).
Martel et al, Inhibition of the Immune Response by Rapamycin, a New Antifungal Antibiotic, Can. J. Physiol. Pharmacol. vol. 55, pp. 48-51 (1977).
Dumont et al, Rapamycin Blocks the Immunosuppressive Effect of FK506 But Not That of Cyclosporin A, FASEB Journal, 5256, vol. 3, No. 4, (1989).
R. Y. Calne et al, Prolonged Survival of Pig Orthotopic Heart Grafts Treated with Cyclosporin A, Lancet, pp. 1183-1185, (Jun. 3, 1978).
Shibata Norikuni,Antifibrosis effect of interferongamma(IFNgamma)and rapamycin(Rapa)in immortal human hepatic stellate cells, Database Biosis Online!, 2002, pp. 185-197, Database accession No. PREV200300151275, ISSN: 0386-5924, vol. 28, pp. 185-197, Biosciences Information Service, Kawasaki Igakkai Shi [Abstract].
S. Jain, et al.,Rapamycin Reduces Expression of Fibrosis-Associated Genes in an Experimental Model of Renal Ischaemia Reperfusion Injury, Transplantation Proceedings, Feb. 2001, pp. 556-558, vol. 22, No. 1-2, ISSN: 0041-1345, Elsevier Science, Inc., New York, NY.
Yoshihide Arisaka,Effects of interferon-.gamma. and rapamycin on transforming growth factor-.beta.-induced liver fibrosis in an organotypic slice culture, Database Chemabs Online!, 2003, pp. 597-603, Database accession No. 2004:146496, ISSN: 0029-0424, vol. 62(11), Nihon Daigaku Igakkai [Abstract].
L. Lopez-Lazarro, et al., F. Lokiec, et al., H.C. Swaisland, et al., U. Mayer, et al., L. Plasswilm, et al., G. Cartei, et al., F. Lokiec, et al., M. Airoldi, et al., J. Boni, et al., O. Tomoyuki, et al., O. Juan, et al., T. Oe, et al.,Pharmacokineticsposter session (12 individual poster titles), European Journal of Cancer, Oct. 2001, pp. S66-S69, vol. 37, Pergamon Press, Oxford, GB [Posters].
Shibata et al, Establishment of an Immortalized Human Hepatic Stellate Cell Line to Develop Antifibrotic Therapies, Cell Transplantation, vol. 12, pp. 499-507, (2003).
Friedman et al, The Virtuosity of Hepatic Stellate Cells, Gastroenterology, vol. 117, No. 5, pp. 1244-1246, (Nov. 1999).
Zhu et al, Rapamycin Inhibits Hepatic Stellate Cell Proliferation in Vitro and Limits Fibrogenesis in an In Vivo Model of Liver Fibrosis, Gastroenterology 117, 5, pp. 1198-1204, (Nov. 1999).

Affiliated with

Also associated with

Rating

Method of treating hepatic fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating hepatic fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating hepatic fibrosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3668596